CSL Ltd. and Vitaeris Inc. have entered into a strategic collaboration and purchase option agreement for the development of clazakizumab for solid organ transplant rejection. Clazakizumab is a humanized, monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6). IL-6 is an important driver of the inflammatory response and is known to play a key role in transplant rejection. Vitaeris will retain control of projects through end of Phase III and will receive $15 million upfront from...